BRPI0407795A - polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol - Google Patents

polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol

Info

Publication number
BRPI0407795A
BRPI0407795A BRPI0407795-4A BRPI0407795A BRPI0407795A BR PI0407795 A BRPI0407795 A BR PI0407795A BR PI0407795 A BRPI0407795 A BR PI0407795A BR PI0407795 A BRPI0407795 A BR PI0407795A
Authority
BR
Brazil
Prior art keywords
pyrrol
substituted
protein kinase
kinase inhibitors
polymers
Prior art date
Application number
BRPI0407795-4A
Other languages
English (en)
Inventor
Changquan Sun
Todd P Foster
Fusen Han
Michael Hawley
Tom Thamann
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BRPI0407795A publication Critical patent/BRPI0407795A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"POLIMORFOS DE INIBIDORES DE PROTEìNA CINASE DE 2-INDOLINONA SUBSTITUìDA COM PIRROL". A presente invenção refere-se polimorfos do composto de 2-indolinona substituída com 3-pirrol de (2-pirrolidin-1-il-etil)-amida de ácido 5-(5-flúor-2-oxo-1,2-dihidro-indol-3-ilidenometil)-2,4-dimetil-1H-pirrol-3- carboxílico.
BRPI0407795-4A 2003-02-24 2004-02-23 polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol BRPI0407795A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886303P 2003-02-24 2003-02-24
US10/776,337 US7452913B2 (en) 2003-02-24 2004-02-12 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
PCT/US2004/005281 WO2004076410A2 (en) 2003-02-24 2004-02-23 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0407795A true BRPI0407795A (pt) 2006-02-14

Family

ID=32930498

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407795-4A BRPI0407795A (pt) 2003-02-24 2004-02-23 polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol

Country Status (14)

Country Link
US (2) US7452913B2 (pt)
EP (2) EP1599200A4 (pt)
JP (1) JP2006518755A (pt)
KR (1) KR20050107588A (pt)
AU (1) AU2004215407C1 (pt)
BR (1) BRPI0407795A (pt)
CA (1) CA2516900A1 (pt)
MX (1) MXPA05008959A (pt)
NO (1) NO20054071L (pt)
NZ (1) NZ541720A (pt)
PL (1) PL378570A1 (pt)
RU (1) RU2335502C2 (pt)
WO (1) WO2004076410A2 (pt)
ZA (1) ZA200506370B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
KR101050906B1 (ko) * 2005-09-19 2011-07-20 화이자 프로덕츠 인크. 피롤 치환된 2-인돌리논의 고체 염 형태
TWI387019B (zh) * 2007-08-02 2013-02-21 日月光半導體製造股份有限公司 在基材上形成穿導孔之方法
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2545034A1 (en) 2010-03-10 2013-01-16 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
ATE331514T1 (de) * 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US7119209B2 (en) * 2002-02-15 2006-10-10 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
WO2004076410A8 (en) 2005-10-20
JP2006518755A (ja) 2006-08-17
US20090048327A1 (en) 2009-02-19
CA2516900A1 (en) 2004-09-10
NO20054071D0 (no) 2005-09-01
AU2004215407C1 (en) 2009-07-09
WO2004076410A3 (en) 2005-03-03
NZ541720A (en) 2009-02-28
AU2004215407A1 (en) 2004-09-10
PL378570A1 (pl) 2006-05-02
EP1599200A2 (en) 2005-11-30
HK1086486A1 (en) 2006-09-22
ZA200506370B (en) 2006-12-27
EP1599200A4 (en) 2007-02-07
KR20050107588A (ko) 2005-11-14
RU2335502C2 (ru) 2008-10-10
MXPA05008959A (es) 2005-11-04
EP2258699A1 (en) 2010-12-08
RU2005129743A (ru) 2006-02-10
US20040259929A1 (en) 2004-12-23
WO2004076410A2 (en) 2004-09-10
US7452913B2 (en) 2008-11-18
NO20054071L (no) 2005-10-13

Similar Documents

Publication Publication Date Title
BRPI0519597A2 (pt) derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose
DE60217147D1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
NO20072965L (no) Potentiatorer av glutamatreceptorer
PT2090575E (pt) Inibidores de erbb
TW200626559A (en) Anilino-pyrimidine analogs
EP2038286A4 (en) Pyrrolo [1,2-B] pyridazinone COMPOUNDS
ATE508119T1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
MX2007003377A (es) Agonistas del receptor de trombopoyetina.
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
EA200802210A1 (ru) Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
BRPI0407795A (pt) polimorfos de inibidores de proteìna cinase de 2-indolinona substituìda com pirrol
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE496056T1 (de) Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
ATE411994T1 (de) Herstellung eines substituierten chinoxalins von hoher reinheit
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
BRPI0416678A (pt) pirazolpirimidinas
BRPI0509731A (pt) pirazol[4,3-d]pirimidinas
ATE469896T1 (de) Aminosäuresalze von rosiglitazon
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
CY1109326T1 (el) Στερεες μορφες αλατος μια πυρρολο υποκατεστημενης 2-ινδολινονης
AR043230A1 (es) Polimorfos de inhibidores de proteina quinasa de 2- indolinona sustituido con pirrol
MA30656B1 (fr) Composes organiques

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/404; C07D 403/14; A61P 35/00

Ipc: A61K 31/404 (2011.01), C07D 403/14 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.